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52 Poster Session Ipost HSCT. CD41 recovery appears to occur at a pace comparable
to that of matched-sibling HSCT recipients. This 2 step procedure
promotes the establishment of donor-recipient tolerance by in vivo
CTX exposure, but avoids any effects of G-CSF on donor lympho-
cytes, allows delivery of a precise dose of T cells to all patients, and
eliminates CTX exposure of the hematopoietic precursors. Patients
who lack matched-sibling donors can be successfully transplanted
on this protocol with little significant GVHD. Infection and relapse
remain problems, but likely can be reduced through transplantation
of patients earlier in their disease course.
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Grade Outcome19 AML - PIF Myeloablative 2.0 1.41 0.26 0 Died-Relapse
@ d 1 6755 CML & AML - PIF Myeloablative 2.0 3.62 5.0 I NED @ d 1 29826 ALL - CR2 Myeloablative 2.0 2.16 6.9 II NED @ d 1 22144 AML - CR2 Myeloablative 1.8 3.83 4.4 II NED @ d 1 18632 SAA Myeloablative 2.0 1.72 0.13 III Died-Infection
@ d 1 10159 AML - Resist
Relapse 1Myeloablative 2.0 4.11 0.39 0 Died-Relapse
@ d 1 9160 Biph Leuk -
Resist Relapse 1Myeloablative 2.0 2.74 0.82 I Died-Infection
@ d 1 4248 AML-PIF Myeloablative 2.0 4.57 0.29 I NED @ d 1 5358 AML-CR2 Myeloablative 2.0 3.04 0.27 0 NED @ d 1 4667 AML-PIF Non-myeloablative 2.0 4.33 4.5 II Alive @ d 1
166-Relapse73 AML-PIF Non-myeloablative 2.0 4.38 0.059 0 Died-Relapse
@ d 1 5536 AML-Relapse
post Match
Sib HSCT
Non-myeloablative 2.0 3.04 0.01 0 NED @ d 1 19136
OptiMatch – OPTIMIZED SELECTION OF ALLELE MATCHED UNRE-
LATED DONORS FROM A LARGE DATABASE
Bochtler,W., Eberhard, H.-P., Beth,M.,Mueller, C.R. ZKRDZentrales
Knochenmarkspender-Register Deutschland, Ulm, Germany.
The standard for unrelated donor selection is defined by allele
level matching for, at least, HLA-A, -B and -DRB1 with a strong
tendency to also include HLA-C and/or -DQB1. Even for patients
where such donors will likely exist, the search is hampered by the
high prevalence of donors where some of these loci are only typed
at intermediate or low resolution, by serology or not at all. A large
registry like ZKRDwith over 3million donors can have lists of hun-
dreds or even thousands of similar donor candidates for a substantial
fraction of the patients making an efficient search strategy difficult.
ZKRD’s new OptiMatch system addresses the issues raised by
a three layer concept:
(1) The DNA-based search engine uses serology-to-DNA map-
ping for the identification of donor candidates. The degree of
matching can be determined using combinatorial or biostatistical
methods. Moreover, the probability of allele level matching of
each candidate can not only be determined for each locus based
on the allele frequencies of the German population but also much
more reliably based on allele resolution haplotype frequencies for
HLA-A-B-DRB1, HLA-C-B and HLA-DRB1-DQB1.
(2) The web-based front end allows extensive configuration of the
way match lists are filtered and sorted, for example: Primary match-
ing can be based on the probability of matching 6/6, 8/8 (including
C or DQB1) or 10/10 (including both) alleles, and then the proba-
bility of 1 or, finally, 2 allele mismatches. Filters can be applied for
gender, CMV status and loci already typed.
(3) The sophisticated security architecture is based on strong au-
thentication of users and encrypted data transmission.The new OptiMatch search engine has been in use since late
2006. Its ability to identify some very likely matching donors among
myriads of multiple allele codes gives a stunning power to profes-
sional search coordinators. Even inmost difficult cases it is apparent
upfront which degree of matching can possibly be sought for, which
donors should be considered first and which time frame and cost
volume should be expected.
During its ongoing test phase, the web-based front end is only
available in ZKRD’s intranet but will be released to outside beta tes-
ters before the end of 2007.137
POTENTIAL ROLE OF A MISMATCHED HLA-SPECIFIC CTL CLONE DEVEL-
OPED PRE-TRANSPLANT IN GRAFT REJECTION FOLLOWING CORD
BLOOD TRANSPLANTATION
Murata, M., Narimatsu, H., Terakura, S., Sugimoto, K., Naoe, T. Na-
goya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Graft rejection is a significant complication in cord blood trans-
plantation (CBT), but little is known about the mechanism of rejec-
tion. In the present study, to investigate the potential role of T
lymphocytes in graft rejection, we isolated a CD81 cytotoxicT lym-
phocyte (CTL) clone from a patient with graft rejection after CBT
from an HLA-mismatched unrelated donor. Peripheral blood
mononuclear cells (PBMCs) obtained from the patient just after
the onset of graft rejection were cultured in interleukin-2 contain-
ing media without stimulator cells, and two CTL clones were iso-
lated by limiting dilution. One clone, designated N19D8, lysed
Epstein Barr virus transformed lymphoblastoid cells (B-LCL)
from the donor, but failed to lyse B-LCL from the patient, suggest-
ing that this CTL clone has the possibility of involvement in the im-
munological graft rejection. Fluorescent in situ hybridization for sex
chromosome indicated that N19D8 clone was originated from the
patient. In a cytotoxicity assay, N19D8 CTL lysed all of four B-
LCL lines from unrelated individuals that shared HLA-B*1501
but failed to lyse B-LCL from eight unrelated individuals without
B*1501. These data suggested that N19D8 CTL recognized
HLA-B*1501 molecule as an alloantigen, which was expressed in
donor cells but not in patient cells. The patient B-LCL transfected
withHLA-B*1501 cDNA alone were clearly lysed by N19D8 CTL,
and COS cells transfected with HLA-B*1501 cDNA alone stimu-
lated interferon-g production ofN19D8CTL.Thus, we concluded
that the N19D8 CTL clone recognizes mismatched HLA-B*1501
molecule as an alloantigen. We next determine whether the
N19D8 clone was developed prior to transplantation. The micro-
chimerism analyses specific for HLA-B*1501 gene and PCR assays
specific for the N19D8 CTL clone’s uniquely rearranged T cell re-
ceptor Vb17 chain gene on DNA from pre-transplant PBMCs re-
vealed that the patient was exposed to HLA-B*1501 prior to CBT
andN19D8 clone was developed in the patient’s blood before trans-
plantation. Interestingly, her daughter has HLA-B*1501 in an in-
herited paternal allele, suggesting that the patient might be
exposed to HLA-B*1501 during her pregnancy. In conclusion, the
present study demonstrated the potential role of pre-transplant
CTL in graft rejection following CBT. Further studies focusing
on mismatched HLA-specific CTLs should help establish the opti-
mal strategy to overcome graft rejection in CBT.138
CHARACTERISTICS OF 11 CASES OF PRE-ENGRAFTMENT LYMPHOCYTO-
SIS AFTER REDUCED-INTENSITY CORD BLOOD TRANSPLANTATION
Yamamoto, H., Wake, A., Ishiwata, K., Tuji, M., Takagi, S., Kato, D.,
Matsuhashi, Y., Sea, S., Matsuno, N., Uchida, N., Masuoka, K.,
Yoneyama, A., Taniguchi, S. Toranomon Hospital, Minato-ku Torano-
mon, Tokyo, Japan.
Wehave reported higher incidence of immune-mediated compli-
cations, such as pre-engraftment immune reaction (PIR), character-
ized by high-grade fever, skin eruption, diarrhea, jaundice and body
weight gain developing before engraftment or hemophagocytic
Poster Session I 53syndrome (HPS) early after cord blood transplantation (CBT). Al-
though both can be serious and potentially fatal, not much data have
been available regarding their mechanisms underlying them. Re-
cently, we observed a group of patients who presented relative lym-
phocytosis (LC) early after CBTbefore engraftment.We decided to
conduct a retrospective analysis of those who presented LC early af-
ter transplant to characterize clinical features and to evaluate possi-
ble relevance to abovementioned immune-mediated complications.
Patients and Definition: Patients who underwent RI-CBT at
our institute from Jan.2005 to July 2007 were retrospectively re-
viewed. LC was defined by early lymphocyte-dominant ($80%) in-
crease of WBC for at least 3 consecutive days. Lymphocyte count
must be over 200/ul at least once. Result: We observed 11 cases
who presented LC. Eight out of 11 were of donor-type and 3 of re-
cipient-type chimerism. Median onset of LC of donor cells was 8.5
(8–10) days, and the maximum number of lymphocyte was 519
(242–2828)/ul, primarily CD3-positive T cells with CD4–81 dom-
inancy (60.6(13–68.1)%). Fever and diarrhea were observed in all
patients, liver damage in 7, skin eruption in 4, and HPS in 6. Six
out of 8 experienced graft failure, whereas the remaining 2 experi-
enced severe acute GVHD, resulted in 6 early death up to 50 days
post-transplant. LC of recipient cells developed on median 13
(12–16) days post-transplant, and themaximumnumber of lympho-
cyte was 550 (280–880)/ul, in which CD4–81 cells dominated
(93.1(83.1–96.6)%). All 3 experienced graft rejection and 2 of
them were rescued by second RI-CBT, while 1 died of infection.
Conclusion: LC of either donor- or recipient-derived was sugges-
tive of high incidence of graft failure. Further analyses are currently
going on to investigate possible relevance of LC to PIR or HPS.
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HOWREALISTIC IS IT TO EXPECT A FULLY ALLELE LEVELMATCHEDDO-
NOR FROM A SEARCH THROUGH THE NMDP? A 10 YEAR, SINGLE INSTI-
TUTION EXPERIENCE
Askar, M.1, Sobecks, R.2, Kalaycio, M.2, Dean, R.2, Copelan, E.2,
Rybicki, L.3, Pohlman, B.2, Bolwell, B.2 1Transplant Center; 2Taussig
Cancer Center; 3Cleveland Clinic.
TheNationalMarrowDonor Program (NMDP) continues to ex-
pand its donor pool. Transplant outcome correlates with the degree
of HLA matching. Ideally, NMDP searches result in fully matched
donors at the allele level. The odds of finding such a donor, how-
ever, has not been widely discussed.
We performed a retrospective analysis of 517 searches to the
NMDP fromNovember, 1996 through November, 2006. Of these,
213 resulted in a transplant. This analysis is limited to the patients
that actually proceeded to transplant because of multiple potential
reasons beyond HLA matching that may have prevented patients
from receiving a transplant. Only 36 (17%) of 213 transplanted pa-
tients had donors that were fully matched at the allele level. Ninety-
four (44%) patients were mismatched at only DP. Sixty-seven
(31%) patients had a class 1, or DRB1mismatch. The median dura-
tion from the initiation from NMDP search to transplant was 5.2
months. We conclude that finding fully matched donors is still
a challenge, and highlights the need for continued recruitment
for volunteers to the NMDP registry. Indeed, a result of 17% is
likely an overestimate of the number of fully matched searches, be-
cause this analysis only included the patients who proceeded to
transplant. Additionally, 8/8 matched donors with DP mismatches
are common.
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BORTEZOMIB PLUS TACROLIMUS/METHOTREXATE FOR PROPHYLAXIS
OF ACUTE GVHD AFTER HLA MISMATCHED ALLOGENEIC NON-MYELOA-
BLATIVE TRANSPLANTATION: RESULTS OF A DOSE FINDING PHASE I
STUDY
Koreth, J.1, Kim, H.T.2, Ho, V.T.1, Cutler, C.S.1, Soiffer, R.J.1,
Antin, J.H.1, Alyea, E.P.1 1Dana Farber Cancer Institute, Boston,
MA; 2Dana Farber Cancer Institute, Boston, MA.
There is a need for better control of graft versus host disease
(GVHD) after HLA mismatched peripheral blood stem cell
(PBSC) allogeneic transplantation. Bortezomib is a small moleculeproteasome inhibitor approved for treatment of multiple myeloma.
It has immunomodulatory properties, and preclinical data indicate
utility in GVHD control after allogeneic transplantation. Here we
report the dose finding portion of a Phase I/II trial of bortezomib
(dose levels A, B, C: 1, 1.3, 1.5 mg/m2) plus tacrolimus and mini-
methotrexate for GVHD prophylaxis after HLA mismatched non
myeloablative allogeneic stem cell transplantation (NST) for pa-
tients with hematologic malignancies. Dose limiting toxicity
(DLT) by day 45 post PBSC infusion is the primary endpoint,
both acute bortezomib toxicity (e.g. neuropathy) and negative im-
pact on stem cell function (e.g. delayed neutrophil recovery or
poor donor engraftment) in the absence of disease progression. Sec-
ondary endpoints include incidence of acute and chronic GVHD.
Patients with 1–2 locus antigen/allele mismatch (HLA-A, -B, -C,
-DRB1) were eligible. Pretransplant conditioning was busulfex (0.8
mg/kg/d) and fludarabine (30 mg/m2/d) each for 4 days. GVHD
prophylaxis was bortezomib per dose level (day 11, 14, 17) plus
tacrolimus (day –3 to 1180) and mini-methotrexate (5 mg/m2 on
day 11, 13, 16, 111).
13 patients were enrolled. No neurotoxicity was noted. At dose
level A, 1 of 5 patients had a possible DLT, with poor engraftment
likely related to progression of underlying MDS/AML. At dose
level B, 0 of 3 patients had a DLT. At dose level C, 2 of 5 patients
had a DLT. One patient, with minimally treated myeloproliferative
disease failed to engraft; another patient, with CLL, experienced an
immunologic graft rejection.
Grade 2–4 aGVHD occurred in 2 of 13 patients (1 each at dose
level A and C). Chronic GVHD occurred in 3 patients, all at dose
level A, albeit with limited follow up. Disease relapse has occurred
in 5 patients (2 of whomdied), one at dose level B, and 2 each at dose
levels A and C. In summary, GVHD prophylaxis with bortezomib
1.3 mg/m2 plus tacrolimus/mini-methotrexate is convenient and
well tolerated after busulfex/fludarabine conditioning in HLA mis-
matched NST. It may have efficacy in GVHD control, and phase II
accrual is proceeding.LATE EFFECTS/QUALITY OF LIFE141
SIMILAR RISKS FOR HYPOTHYROIDISM IN MYELOABLATIVE AND RE-
DUCED-INTENSITY ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT
SURVIVORS
Al-Hazzouri, A., Cao, Q., Burns, L.J., Weisdorf, D.J., Majhail, N.S.
University of Minnesota, Minneapolis, MN.
Upto 15% of adult myeloablative (MA) allogeneic hematopoietic
cell transplant (HCT) survivors can develop hypothyroidism. HCT
using reduced-intensity conditioning (RIC) is associated with lower
morbidity and mortality, but the risk of hypothyroidism after RIC
HCT is not known. We conducted a retrospective cohort study
to compare the incidence of hypothyroidism after MA and RIC
HCT. Adult allogeneic HCT recipients were eligible if (1) they
had received an allogeneic HCT using a total body irradiation
(TBI) based MA or RIC regimen between 2000 and 2005, (2) sur-
vived for$1 year post-HCT, and (3) had no history of hypothyroid-
ism pre-HCT. TBI dose in MA and RIC regimens was 1320 cGy
(165 cGy twice daily 4 days) and 200 cGy (single fraction), respec-
tively. Hypothyroidism was classified as subclinical (elevated thy-
roid stimulating hormone [TSH] and normal free thyroxine
[FT4]) or overt (elevated TSH and low FT4). All patients had thy-
roid studies performed at least annually after HCT; if clinically in-
dicated, more frequent assessments were conducted at the
discretion of the treating physician. Study eligibility criteria were
met by 181 patients (MA 5 84, RIC 5 97); median follow-up was
28 (range, 12–75) months for MA and 25 (range, 12–67) months
for RIC group. MA recipients were younger (median age 37 vs.
54 years, P \ 0.01), the two groups were otherwise comparable
with respect to gender, race, HCT co-morbidity index scores, dis-
ease status, donor source and incidences of acute and chronic
GVHD. Eleven patients developed hypothyroidism (subclinical -
9, overt - 2). The 3-year cumulative incidence of hypothyroidism
was 8% (95% confidence intervals [CI], 1–14%) in MA and 5%
(95%CI, 0–11%) in RIC groups (p5 0.41). Inmultivariate analyses
that included age, gender, race, conditioning regimen intensity,
